about
Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancerMutational profiling of kinases in glioblastoma.Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patientsDeregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimusEmergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancerReplacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responsesGenetic targeting of the kinase activity of the Met receptor in cancer cellsAcquired resistance to EGFR-targeted therapies in colorectal cancerWild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies.The prognostic IDH1( R132 ) mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma.Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab.Toll-like receptor 9 agonist IMO cooperates with cetuximab in K-ras mutant colorectal and pancreatic cancers.Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma.CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours.High frequency of mutations of the PIK3CA gene in human cancersMutational analysis of the tyrosine kinome in colorectal cancers
P50
Q21142734-1B18DD60-282B-47F7-9750-EA36EA69BAC4Q21261249-912ECE0D-6836-42E4-A9D2-771182232F6AQ24561669-30D32417-4565-4487-A066-D4A33EC805EAQ24600932-EFE8C855-A2B7-44F3-BD09-0D01CDE5F9EAQ24604601-16B3BC6A-30F3-4A49-9AB2-55C693E5E12CQ24658420-658260BD-529A-4F83-9AC3-66A7688090CBQ24675200-6F3262F3-2D6F-40E9-9868-CA12A05057DBQ27022741-1A8C3CA5-9E02-4D50-84D0-A086E6493366Q27851456-4999BDDD-CE5D-4B0E-9A36-EC7602774C7AQ27851465-81F8A377-1CAF-4014-AC50-84F083E8DB13Q27851550-139012E7-9E91-437D-86F8-4EC250E966A9Q27851573-B033F386-F85A-4719-A504-A21B61B58571Q27851587-B25B168F-29A7-4369-B674-48B5483EF923Q27851667-B7EBD207-16FD-4C81-8D6E-D6DA53721EC3Q27851711-5A95E186-92F1-4084-9BA5-9C710FAE7238Q27851787-4066E0D2-25D3-48D5-BFAE-98965DA0F889Q27852990-366B3E1B-EB99-4457-B3C8-8B0D95C7E402Q27853338-5C2E49C1-E92C-4D29-96C7-87B45F452D30Q28131776-01D1041A-4654-42FB-925B-BC3EF8EABC7CQ28203425-B946B09F-2226-46B0-AA15-F67A4E1007FC
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Alberto Bardelli
@ast
Alberto Bardelli
@en
Alberto Bardelli
@es
Alberto Bardelli
@nl
Alberto Bardelli
@sl
type
label
Alberto Bardelli
@ast
Alberto Bardelli
@en
Alberto Bardelli
@es
Alberto Bardelli
@nl
Alberto Bardelli
@sl
prefLabel
Alberto Bardelli
@ast
Alberto Bardelli
@en
Alberto Bardelli
@es
Alberto Bardelli
@nl
Alberto Bardelli
@sl